Cytiva, a biopharma research and manufacturing specialist, rolled out a new cell therapy manufacturing platform the company developed as part of a collaboration with Gilead Sciences’ Kite Pharma unit.
BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on ...
DUBLIN--(BUSINESS WIRE)--The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CAR T-cell Therapy was estimated ...
StockStory.org on MSN
Automobile Manufacturing Stocks Q3 Teardown: Winnebago (NYSE:WGO) Vs The Rest
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the automobile manufacturing stocks, including ...
Paris-based Astraveus formed a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate The Lakhesys Benchtop Cell Factory™ ...
Japan will be able to domestically manufacture therapeutic formulations of CAR-T treatments, a type of immunotherapy that is becoming more commonly used due to its effectiveness against relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback